Cero Therapeutics Holdings Inc. has announced a significant expansion of its intellectual property portfolio with the granting of two U.S. patents and the allowance of a European patent application. These developments pertain to the company's lead compound, CER-1236, and contribute to a total of 18 issued patents and allowed applications internationally, encompassing nine patent families. The newly granted U.S. Patent No. 12,303,551, titled "CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF," covers combination therapies involving CER-1236 for cancer treatment. The company's intellectual property now has protection extending to 2042 in the United States.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.